Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

7 treatments under study, led by 577nm Pascal Laser

Research Leaders

5 sponsors active, led by Federal University of Rio Grande do Sul

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 77/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

4Total

Not Applicable (1)

Phase 1 (1)

Phase 2 (1)

Phase 3 (1)

Trial Status

Completed2

Terminated1

Unknown1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials

NCT03845049Phase 3TerminatedPrimary

Comparative Multicenter Randomized Study of Aflibercept Versus Placebo in Macular Telangiectasia Type 1

NCT03321916Not ApplicableCompletedPrimary

MacTel Laser Study

NCT01975103Phase 2Unknown

Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases

NCT00685854Phase 1CompletedPrimary

Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

Showing all 4 trials

Research Network

Common Treatments

577nm Pascal Laser1
Sham Injection1
Topcon Endpoint Management1
Examinations During Study Every Month1
Aflibercept1

Active Sponsors

Federal University of Rio Grande do Sul1
The Lowy Medical Research Institute Limited1
Centre Hospitalier Universitaire Dijon1
Centre Hospitalier Universitaire De Dijon1
National Eye Institute (NEI)1

Macular Telangiectasia